Novacyt S.A. New COVID-19 variant (2631J)
21 December 2020 - 06:00PM
UK Regulatory
TIDMNCYT
RNS Number : 2631J
Novacyt S.A.
21 December 2020
Novacyt S.A.
("Novacyt", the "Company" or the "Group")
COVID-19 diagnostic tests remain able to detect all published
virus strains
Paris, France and Camberley, UK - 21 December 2020 - Novacyt
(EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in
clinical diagnostics, announces that following the detection of a
new variant of COVID-19 by the UK's COVID-19 Genomics UK
consortium, known as VUI-202012/01, the Company has carried out a
detailed analysis of the mutations in this new variant and in all
published COVID-19 strains to fully assess the reliability of its
existing diagnostic tests.
The results of the in silico (computer simulation) analysis of
the sequenced mutations show that the Company's polymerase chain
reaction product portfolio, based around a single and a two gene
target for COVID-19, remain able to detect all published COVID-19
strains with the same high level of accuracy, including
VUI-202012/01.
The Company notes this new strain of the virus has also been
identified in other countries, including the Netherlands, Denmark
and Australia.
Graham Mullis , Chief Executive Officer of Novacyt,
commented:
"These data support the continued use of our tests, which remain
accurate in detecting all published strains of COVID-19, including
the latest variant. As part of our surveillance programme, we are
committed to analysing our selected gene targets for COVID-19
against new published viral sequences to demonstrate ongoing
accuracy and performance. We also remain in close contact with the
Department of Health and Social Care and the NHS as we continue to
focus our efforts on deploying our tests to hospitals and
laboratories across the UK, as well as to our customers around the
world."
Contacts
Novacyt SA
Graham Mullis, Chief Executive Officer
Anthony Dyer, Chief Financial Officer
+44 (0)1276 600081
SP Angel Corporate Finance LLP (Nominated Adviser and
Broker)
Matthew Johnson / Charlie Bouverat (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
+44 (0)20 3470 0470
Numis Securities Limited (Joint Broker)
Freddie Barnfield / James Black
+44 (0)20 7260 1000
Allegra Finance (French Listing Sponsor)
Rémi Durgetto / Yannick Petit
+33 (1) 42 22 10 10
r.durgetto@allegrafinance.com / y.petit@allegrafinance.com
FTI Consulting (International)
Victoria Foster Mitchell / Alex Shaw / Mary Whittow
+44 (0)20 3727 1000
victoria.fostermitchell@fticonsulting.com /
alex.shaw@fticonsulting.com / mary.whittow@fticonsulting.com
FTI Consulting (France)
Arnaud de Cheffontaines
+33 (0)147 03 69 48
arnaud.decheffontaines@fticonsulting.com
About Novacyt Group
The Novacyt Group is an international diagnostics business
generating an increasing portfolio of in vitro and molecular
diagnostic tests. Its core strengths lie in diagnostics product
development, commercialisation, contract design and manufacturing.
The Company's lead business units comprise of Primerdesign and
Lab21 Products, supplying an extensive range of high quality assays
and reagents worldwide. The Group directly serves microbiology,
haematology and serology markets as do its global partners, which
include major corporates.
For more information please refer to the website:
www.novacyt.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
UPDKKKBNNBDBDBB
(END) Dow Jones Newswires
December 21, 2020 02:00 ET (07:00 GMT)
Novacyt (LSE:NCYT)
Historical Stock Chart
From Feb 2024 to Mar 2024
Novacyt (LSE:NCYT)
Historical Stock Chart
From Mar 2023 to Mar 2024